Genflow Biosciences Plc (GB:GENF) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genflow Biosciences Plc has secured €4 million in non-dilutive funding from the Wallonia region to advance its gene therapy, GF-1002, aimed at treating Metabolic Associated Steatohepatitis (MASH). This financial boost includes a research grant and a repayable advance, covering substantial development costs and marking a significant step forward for the company. The support underscores the innovation and potential of Genflow’s approach in an area with limited treatment options.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- Intel Stock (NASDAQ:INTC) Slips Despite Growing Interest in AI
- “…Tied to the Effort From the Administration” Boeing Stock (NYSE:BA) Blasts Up as Boeing Counts on New Top Sales Rep in China: President Trump
- “We Do Not Have Conflicting Interests….” Microsoft Stock (NASDAQ:MSFT) Gains on New Plan to be the Agentic AI Internet’s Backbone